1. Home
  2. ZWS vs DVA Comparison

ZWS vs DVA Comparison

Compare ZWS & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zurn Elkay Water Solutions Corporation

ZWS

Zurn Elkay Water Solutions Corporation

HOLD

Current Price

$46.74

Market Cap

8.0B

Sector

Industrials

ML Signal

HOLD

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$106.43

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZWS
DVA
Founded
1891
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Misc Health and Biotechnology Services
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
8.2B
IPO Year
2012
1995

Fundamental Metrics

Financial Performance
Metric
ZWS
DVA
Price
$46.74
$106.43
Analyst Decision
Buy
Hold
Analyst Count
6
4
Target Price
$47.50
$145.00
AVG Volume (30 Days)
877.8K
813.3K
Earning Date
02-03-2026
02-12-2026
Dividend Yield
0.95%
N/A
EPS Growth
42.52
5.63
EPS
1.12
9.76
Revenue
$1,659,400,000.00
$13,317,965,000.00
Revenue This Year
$9.03
$6.50
Revenue Next Year
$5.39
$2.97
P/E Ratio
$42.47
$10.64
Revenue Growth
6.88
5.14
52 Week Low
$27.74
$101.00
52 Week High
$50.03
$179.60

Technical Indicators

Market Signals
Indicator
ZWS
DVA
Relative Strength Index (RSI) 49.59 36.93
Support Level $45.80 $103.48
Resistance Level $47.53 $106.38
Average True Range (ATR) 1.06 3.15
MACD 0.02 -0.51
Stochastic Oscillator 67.15 37.21

Price Performance

Historical Comparison
ZWS
DVA

About ZWS Zurn Elkay Water Solutions Corporation

Zurn Elkay Water Solutions Corp designs procures, manufactures, and markets a range of clean water solutions for drinking water, hygiene, and sustainable water management. The company's product portfolio includes professional-grade water control and safety, water distribution and drainage, drinking water, finish plumbing, hygienic, environmental and site works products for public and private spaces.

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

Share on Social Networks: